Stock analysts at Citigroup started coverage on shares of Radius Health (NASDAQ:RDUS) in a research note issued to investors on Wednesday, MarketBeat.com reports. The firm set a “neutral” rating and a $30.00 price target on the biopharmaceutical company’s stock. Citigroup’s price objective would indicate a potential upside of 12.36% from the company’s current price.

A number of other analysts have also commented on the company. Zacks Investment Research lowered Radius Health from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Cantor Fitzgerald restated a “buy” rating and issued a $58.00 price target on shares of Radius Health in a report on Friday, November 3rd. Jefferies Group cut their price target on Radius Health from $38.00 to $31.00 and set a “hold” rating on the stock in a report on Friday, November 3rd. BidaskClub lowered Radius Health from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Finally, Maxim Group restated a “positive” rating on shares of Radius Health in a report on Friday, September 29th. They noted that the move was a valuation call. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. Radius Health currently has a consensus rating of “Hold” and an average price target of $48.00.

Radius Health (NASDAQ:RDUS) traded down $0.57 during mid-day trading on Wednesday, reaching $26.70. The company’s stock had a trading volume of 1,139,199 shares, compared to its average volume of 962,975. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87. Radius Health has a 52-week low of $24.66 and a 52-week high of $55.00.

Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The business had revenue of $13.50 million during the quarter, compared to analysts’ expectations of $6.90 million. During the same quarter in the previous year, the company posted ($1.07) EPS. analysts predict that Radius Health will post -5.57 earnings per share for the current year.

In related news, major shareholder Growth N. V. Biotech bought 50,000 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were acquired at an average price of $26.25 per share, with a total value of $1,312,500.00. Following the completion of the transaction, the insider now owns 5,698,799 shares in the company, valued at $149,593,473.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Jose Carmona bought 3,000 shares of the stock in a transaction that occurred on Thursday, September 14th. The stock was bought at an average cost of $32.83 per share, for a total transaction of $98,490.00. Following the transaction, the chief financial officer now owns 3,000 shares of the company’s stock, valued at approximately $98,490. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 367,678 shares of company stock worth $11,746,498. 15.00% of the stock is owned by company insiders.

Large investors have recently added to or reduced their stakes in the stock. State of Wisconsin Investment Board acquired a new stake in shares of Radius Health in the second quarter valued at about $1,176,000. Candriam Luxembourg S.C.A. increased its position in shares of Radius Health by 23.5% in the third quarter. Candriam Luxembourg S.C.A. now owns 142,000 shares of the biopharmaceutical company’s stock valued at $5,474,000 after acquiring an additional 27,000 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Radius Health by 4.5% in the second quarter. Vanguard Group Inc. now owns 3,145,717 shares of the biopharmaceutical company’s stock valued at $142,281,000 after acquiring an additional 135,071 shares during the last quarter. State Street Corp increased its position in shares of Radius Health by 12.9% in the second quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock valued at $84,473,000 after acquiring an additional 213,399 shares during the last quarter. Finally, BlackRock Inc. increased its position in shares of Radius Health by 10.0% in the second quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock valued at $130,881,000 after acquiring an additional 262,896 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: “Citigroup Begins Coverage on Radius Health (RDUS)” was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/06/citigroup-begins-coverage-on-radius-health-rdus.html.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.